Intradermal or intravenous administration typically requires 1–2 hours; patients often resume light activity same-day. Mild localised inflammation or fatigue within 24–48 hours is commonly reported. No extended downtime is expected. However, onset of any symptomatic benefit is gradual, unfolding over weeks rather than days. Immediate post-procedure monitoring protocols differ between clinics.
Approximately 10 registered trials are investigating stem cell and exosome therapies for menopause-related symptoms. A 2023 small-scale study of placental MSCs reported subjective improvement in hot flush frequency in 70% of participants over 12 weeks, though follow-up assessments remain limited. Exosome trials have focused on anti-inflammatory signalling rather than direct hormone replacement. No large multicentre randomised controlled trials have yet demonstrated safety or efficacy comparable to hormone therapy, and recruitment for new menopause-focused stem cell studies has stalled. Evidence remains preliminary and largely mechanistic.
Sunt un candidat? → · Menopause & Hormonal Health: full overview → · Cost Menopauza și Sănătatea Hormonală → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită